Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

BACKGROUND: We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. METHODS: Retrospective review (May 2014–December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kapl...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Inflamm Bowel Dis
Main Authors: Shmidt, Eugenia, Kochhar, Gursimran, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Chaudrey, Khadija, Koliani-Pace, Jenna L, Hirten, Robert, Faleck, David, Barocas, Morris, Luo, Michelle, Lasch, Karen, Boland, Brigid S, Singh, Siddharth, Vande Casteele, Niels, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V, Sandborn, William J, Siegel, Corey A, Sands, Bruce E, Colombel, Jean-Frederic, Shen, Bo, Dulai, Parambir S
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2018
נושאים:
Original Clinical Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693035/
https://ncbi.nlm.nih.gov/pubmed/29788240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy171
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים